Neurology Central

FENS 2018: Epigenetic target identified in early treatment of Alzheimer’s disease

An international team of researchers, primarily based in the École Polytechnique Fédérale de Lausanne (Lausanne, Switzerland), have identified an epigenetic modification that could be manipulated early on in the progression of Alzheimer’s disease (AD) through the use of a dietary drug, potentially leading to a more effective treatment of the disease.

There are currently almost 50 million people worldwide living with dementia, including AD, and this figure is expected to rise to over 131.5 million by 2020. AD is often diagnosed after its onset, meaning that treatments only target the symptoms of the disease, not the cause.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.